As stated several times the Combo Trial PE Data is being used to create a pathway for Mono with the FDA. The FDA all but told CYDY to supply PE Data for Combo and additional safety data from the Mono Trial and if results are strong we will consider Pro-140 as a Mono therapy.
Tony and his team believe Pro-140 has the goods to ultimately be approved as a single agent, however they plan on being sold long before approval. If efficacy from Combo PE is achieved and additional safety data from the Mono Trial is clean the tipping point for a buyout will be primed to happen well ahead of the completion of the P3 Mono Trial.
As he has said many times the science and empirical data will dictate our fate. Up to this point only a few posters dispute the science. I trust Tony's judgement much more than anyone on this board. This is his backyard. Unless we hit a negative with efficacy or safety Pro-140 is going to disrupt SOC at some level. This is not a company that is going to zero like Wallstreet posted earlier. The only question is how much will Pro-140 fetch and when will it happen--that is the debate.
News 
Market Data 
Discover 
AI
